A recent review highlights the neurophysical changes associated with immersive virtual reality-induced hypoalgesia for pain management.

Dr Erica Schwartz will lead the CDC following a recent confirmation vote in the Senate confirming her appointment as head of the agency.

Improving and maintaining optimal midlife vascular health is associated with an increased number of dementia-free survival years.

MRI analyses demonstrate that distributed normative brain deviations increase with worsening depression and anxiety symptom severity.

Genome-wide association data reveals a shared genetic foundation between schizophrenia and the use of specific prescription medications.

SAD shares genetic risk with several psychiatric illnesses, but these factors are not linked to common clinical subtypes, such as severity or comorbid MDD.

The FDA has approved Orzeyful (oveporexton), a first-in-class oral orexin receptor 2 agonist, for the treatment of adult narcolepsy type 1.

As autism therapy utilization and spending expand rapidly, federal agencies are pushing for state oversight to manage Medicaid budget policy.

Anxiety symptoms appear to be common among a portion of patients with chronic rhinosinusitis with nasal polyps.

A new data-driven process may help identify patients that can be served safely while seated in the emergency department.

FDA grants Fast Track designation to PVX108, a novel peptide immunotherapy for peanut allergy, supported by phase 1 data and an ongoing phase 2 pediatric trial.

A couple of Michigan residents have died due to cyclosporiasis complications, the first deaths associated with the current outbreak in the US.